Isabella Lorenzetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isabella Lorenzetti has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
A. Mamoli
Department of Neurology 2°, Ospedali Riuniti di Bergamo, Italy
1 shared publication- Alessandro Preti
HMGBiotech S.r.l., 20132 Milan, Italy
1 shared publication Andrea Gorzanelli
Division of Genetics and Cell Biology, Chromatin Dynamics Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
1 shared publication- Angelo Quattrini
Division of Neuroscience IRCCS San Raffaele Scientific Institute Milan Italy
1 shared publication - Anna Rubartelli
Cell Biology Unit, IRCCS AOU San Martino-IST, Genova, Italy
1 shared publication - Carmine Valenza
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy
1 shared publication
Latest Publications
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S1082
2041P The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S1082
2041P The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
- 2 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (596)
Rebalancing expression of HMGB1 redox isoforms to counteract muscular dystrophy
The redox-sensitive HMGB1 protein is a functional link between oxidative stress and persistent inflammation in muscular dystrophies.
- 2 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (596)
Rebalancing expression of HMGB1 redox isoforms to counteract muscular dystrophy
The redox-sensitive HMGB1 protein is a functional link between oxidative stress and persistent inflammation in muscular dystrophies.
- 1 December 1993
- Published by Wiley in Annals of Neurology
- Vol. 34 (6) , 848-854
Serum antibodies to Purkinje cells and dorsal root ganglia neurons in sensory neuronopathy without malignancy
Anti‐Purkinje cell antibodies (APCA), believed to be markers of paraneoplastic cerebellar degeneration in females, have been identified in the serum of 3 men with subacute sensory neuronopathies and no evidence of tumors 5 years after the onset of the neurological signs. By indirect immunohistochemistry on sections of rat cerebellum and dorsal root ganglia, the patients' IgG bound to the cytoplasms of both Purkinje cells and dorsal root ganglia neurons. By western blot analysis on whole human cerebellum and whole human dorsal root ganglia homogenates, the IgG from 2 patients bound to a 62‐kd protein in both homogenates and the IgG from 1 patient bound to a 110‐kd protein in the cerebellum homogenate only. Yo autoantibody test was negative in all patients. Our study provides evidence that non‐anti‐Yo APCA may be associated with subacute sensory neuronoopathies and are not necessarily markers of an underlying tumor. The previously described anti‐Yo APCA has only occurred in females with cancer.
- 1 December 1993
- Published by Wiley in Annals of Neurology
- Vol. 34 (6) , 848-854
Serum antibodies to Purkinje cells and dorsal root ganglia neurons in sensory neuronopathy without malignancy
Anti‐Purkinje cell antibodies (APCA), believed to be markers of paraneoplastic cerebellar degeneration in females, have been identified in the serum of 3 men with subacute sensory neuronopathies and no evidence of tumors 5 years after the onset of the neurological signs. By indirect immunohistochemistry on sections of rat cerebellum and dorsal root ganglia, the patients' IgG bound to the cytoplasms of both Purkinje cells and dorsal root ganglia neurons. By western blot analysis on whole human cerebellum and whole human dorsal root ganglia homogenates, the IgG from 2 patients bound to a 62‐kd protein in both homogenates and the IgG from 1 patient bound to a 110‐kd protein in the cerebellum homogenate only. Yo autoantibody test was negative in all patients. Our study provides evidence that non‐anti‐Yo APCA may be associated with subacute sensory neuronoopathies and are not necessarily markers of an underlying tumor. The previously described anti‐Yo APCA has only occurred in females with cancer.